Analysis and management of drug related problems on a nephrology ward from a pharmacist´s point of view

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078739" target="_blank" >RIV/00023001:_____/19:00078739 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/19:00113857 RIV/00216208:11160/19:10407140 RIV/00209805:_____/19:00078974

Výsledek na webu

<a href="https://www.ingentaconnect.com/contentone/govi/pharmaz/2019/00000074/00000010/art00011" target="_blank" >https://www.ingentaconnect.com/contentone/govi/pharmaz/2019/00000074/00000010/art00011</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1691/ph.2019.9568" target="_blank" >10.1691/ph.2019.9568</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Analysis and management of drug related problems on a nephrology ward from a pharmacist´s point of view

Popis výsledku v původním jazyce

The main goal of the study was to determine the incidence and the character of drug related problems (DRPs) identified in chronic kidney disease patients by the clinical pharmacist at the nephrology department. As secondary objective, the aim was to identify the frequency and character of DRPs of selected high risk drugs in medication reviews. The clinical pharmacist reviewed patients medication records and made drug therapy-related recommendations to physicians. The clinical pharmacists interventions were categorized using an adaptation of the Pharmaceutical Care Network Europe. During the study period (January 2016 - June 2018) the clinical pharmacist performed 1192 interventions in 1870 adult patients admitted to the Nephrology Department. The most frequent DRP was untreated indication 324 (27.18%) of all interventions, and incorrect dose 248 (20.81%). Anti-infectives were identified as the drug category with the highest frequency of interventions. Almost 93% of all interventions were accepted by the attending physicians. Still within the second objectives, underdosing was observed as the most frequent problem for renally excreted drugs. It was found that an incorrect dose is a very frequent issue at the nephrology department. Surprisingly, the main problem was underdosing. In the category of renally excreted drugs, underdosing was observed in antithrombotics and antivirals. The above- mentioned results prove the need of a clinical pharmacist, preferably in sense of maximizing of the treatment effect and improving the care of patients. © 2019 Govi-Verlag Pharmazeutischer Verlag GmbH. All rights reserved.

Název v anglickém jazyce

Analysis and management of drug related problems on a nephrology ward from a pharmacist´s point of view

Popis výsledku anglicky

The main goal of the study was to determine the incidence and the character of drug related problems (DRPs) identified in chronic kidney disease patients by the clinical pharmacist at the nephrology department. As secondary objective, the aim was to identify the frequency and character of DRPs of selected high risk drugs in medication reviews. The clinical pharmacist reviewed patients medication records and made drug therapy-related recommendations to physicians. The clinical pharmacists interventions were categorized using an adaptation of the Pharmaceutical Care Network Europe. During the study period (January 2016 - June 2018) the clinical pharmacist performed 1192 interventions in 1870 adult patients admitted to the Nephrology Department. The most frequent DRP was untreated indication 324 (27.18%) of all interventions, and incorrect dose 248 (20.81%). Anti-infectives were identified as the drug category with the highest frequency of interventions. Almost 93% of all interventions were accepted by the attending physicians. Still within the second objectives, underdosing was observed as the most frequent problem for renally excreted drugs. It was found that an incorrect dose is a very frequent issue at the nephrology department. Surprisingly, the main problem was underdosing. In the category of renally excreted drugs, underdosing was observed in antithrombotics and antivirals. The above- mentioned results prove the need of a clinical pharmacist, preferably in sense of maximizing of the treatment effect and improving the care of patients. © 2019 Govi-Verlag Pharmazeutischer Verlag GmbH. All rights reserved.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmazie

ISSN

0031-7144

e-ISSN

—

Svazek periodika

74

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

5

Strana od-do

625-629

Kód UT WoS článku

000525868800011

EID výsledku v databázi Scopus

2-s2.0-85074545015